Related Experiment Video

Updated: Jun 9, 2026

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability
07:23

Optimization of the Retinal Vein Occlusion Mouse Model to Limit Variability

Published on: August 6, 2021

[The use of anti-angiogenic drugs for central retinal vein occlusion]

Michael Waisbourd, Anat Loewenstein

    Harefuah
    |September 4, 2010
    PubMed

    Insights

    Central retinal vein occlusion (CRVO) treatment guidelines are unclear. Most specialists treat non-ischemic CRVO with macular edema, but fewer treat ischemic CRVO without edema.

    Area of Science:

    • Ophthalmology
    • Retinal diseases
    • Vascular disorders

    Background:

    • Central retinal vein occlusion (CRVO) is a significant cause of vision loss.
    • Macular edema, ischemia, and neovascular glaucoma are primary drivers of decreased vision in CRVO.
    • Anti-vascular endothelial growth factor (VEGF) therapies, introduced in 2005, have improved visual acuity and reduced neovascularization in CRVO.

    Discussion:

    • Lack of clear treatment guidelines for CRVO poses a therapeutic challenge.
    • Israeli retinal specialists' practices reveal varied approaches based on CRVO subtype and visual acuity.
    • Intravitreal anti-VEGF injections are commonly recommended for non-ischemic CRVO with macular edema and reduced vision.

    Key Insights:

    • A majority of specialists initiate anti-VEGF treatment for non-ischemic CRVO with visual acuity ≤6/15 and macular edema.
    • Only 21% of specialists would treat ischemic CRVO with visual acuity ≤6/60 if macular edema is absent.
    • Optical coherence tomography (OCT) is used for follow-up every 4-6 weeks after edema resolution, guiding further treatment decisions.

    Outlook:

    • Further large prospective controlled studies are essential.
    • These studies should clarify optimal timing for initiating and withholding anti-VEGF treatment in CRVO.
    • Establishing recommended treatment intervals for CRVO is crucial for standardized care.

    Related Concept Videos

    Open Angle Glaucoma: Treatment01:27

    Open Angle Glaucoma: Treatment

    In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
    Drugs such as carbonic anhydrase inhibitors, α2- and...
    Diabetic Retinopathy01:27

    Diabetic Retinopathy

    DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
    Angle Closure Glaucoma: Treatment01:28

    Angle Closure Glaucoma: Treatment

    Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
    Regulation of Angiogenesis and Blood Supply01:24

    Regulation of Angiogenesis and Blood Supply

    Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

    Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

    Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
    ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...